Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. - Wikidata - awgldk - TriplyDB

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

http://www.wikidata.org/entity/Q33756929

about

Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease Elderly patients and inflammatory bowel disease Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Rare gastrointestinal lymphomas: The endoscopic investigation Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists Infliximab-Related Infusion Reactions: Systematic Review Use of the tumor necrosis factor-blockers for Crohn's disease Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosis Comparison of pooled risk estimates for adverse effects from different observational study designs: methodological overview Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy.Biological treatment of Crohn's disease.Gamma-delta t-cell lymphomas.TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.Patient preferences for surgical versus medical therapy for ulcerative colitis.Adverse events in IBD: to stop or continue immune suppressant and biologic treatment Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review Failure or success of electronic search strategies to identify adverse effects data.Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up.Management of active Crohn disease.Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Review article: acute severe ulcerative colitis - evidence-based consensus statements.Microbiome associations of therapeutic enteral nutrition.Do inflammatory bowel disease therapies cause cancer?Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor New strategies for treatment of inflammatory bowel disease

P2860

Q22241416-BF6E2D21-0CD4-4227-A48A-FFACDCDB8226 Q24289205-F24A156A-C96B-469D-982E-457F89640A24 Q24631869-E40D1396-3854-412C-9AEA-1255EFE26086 Q26768270-0C9A3655-8FBA-4603-8D40-7E80FB2F4334 Q26776151-5908914E-1A02-49D5-BBE3-20FCB32152FD Q26777409-E16282F4-FA53-4CBC-B477-5A94F54FF817 Q26799041-E2DAB92F-CF27-41E5-B12B-FB130F37FE9D Q26822029-254A6BFE-360E-4A4F-8D3C-20BA54031AB9 Q26823547-2C2F984F-E080-4D4B-BEDE-C588B50EBA36 Q26826827-7F67D53D-2977-4556-B50F-8B837EF1E78B Q26827444-AF47F6AE-C3AD-4175-8138-3478AB34D550 Q26862821-EB4746FF-3CC4-4EAC-A9E8-6D75C79A0985 Q26864906-280C6F34-26D6-48B7-A490-FBC59F2114AE Q26866940-BA662904-5DDB-4605-BBF5-A9A176838480 Q26999078-2D80D989-B50A-41BC-8B0A-92F9583683F8 Q27013835-E3B7FBC2-E2DF-4B10-BE8B-510311D0329E Q27030762-0F7E20EF-18F4-44DD-951F-94A666F71E6A Q28261955-370A7698-F5D1-474C-B64F-73850BCFC8E0 Q28535464-4B030BCD-71E0-4CBE-A3B6-CE28F6FA2756 Q30498145-2B76941C-86D6-4FD2-BAA6-809F6B8FDD07 Q33354991-560A16A2-7A74-4CEA-BD6A-DEDE52DD8D38 Q33417290-CCB57B0C-B6F3-4A09-8DCA-A1C426A0AEBD Q33626895-E27A3AD9-D9A5-4B92-B4B7-F0E3B69F4AEF Q33786255-9C8FFA8C-95FA-433F-A625-056E8BD9897C Q33886458-1089135C-3CB7-4F6B-A40F-C5F614A2AC32 Q33894784-C5BE009D-874C-40AC-A567-519EA448162A Q34065549-AC82F5B4-5962-4E5B-967A-60CF382FB8B2 Q34073191-F0118818-6524-4039-BCD0-49986D3A6A19 Q34078707-BC42300F-6D19-4240-A976-37428672FFA7 Q34137455-3A1B50F3-C6A6-4EF1-BB8A-5039F1B288A1 Q34238325-4FBC0888-DDBB-4B3B-9F6E-3524010B1D51 Q34255507-F7EAB471-379A-40FC-BE1A-E81B671669FF Q34345967-8E2DC916-1E61-48F5-9A00-43EDF9257D7E Q34520662-787E45CA-A372-4F94-896B-B2E3B3E7BDB8 Q34528270-2D0ECB71-0975-4086-9731-65875C971756 Q34578149-9C7A5600-D1D5-40FB-83C2-AC63301913E9 Q34613890-8CD66B05-8583-419A-AEF4-5AA7160286A4 Q35026302-0320BB0E-5BB1-4939-9378-7791D2275401 Q35057027-30C415AB-6167-488A-96D8-A9E84D094135 Q35069777-B0770CCA-45BD-4A5F-A9C0-3DE979039B9C

P2860

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

http://www.wikidata.org/entity/Q33756929

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Risk of lymphoma associated wi ...... hn's disease: a meta-analysis.

@ast

Risk of lymphoma associated wi ...... hn's disease: a meta-analysis.

@en

type

label

Risk of lymphoma associated wi ...... hn's disease: a meta-analysis.

@ast

Risk of lymphoma associated wi ...... hn's disease: a meta-analysis.

@en

prefLabel

Risk of lymphoma associated wi ...... hn's disease: a meta-analysis.

@ast

Risk of lymphoma associated wi ...... hn's disease: a meta-analysis.

@en

P1433

Q33756929-6559FC13-AD26-4E79-8755-6AEF54099668

P1476

Q33756929-987903C8-4D8D-4715-95A8-A88C2BFD84F3

P2093

Q33756929-13E572F5-10A2-412E-A16D-2210B226DC74

Q33756929-4D4F3A3C-9F69-4621-A1BF-EB43A956D8A2

Q33756929-6F493A29-7E49-46BD-9E37-017B50694214

Q33756929-BED53E41-DF49-4830-A980-22EA5A35F505

Q33756929-EDCAE072-9EC3-4824-BE48-922D0328C0EF

P2860

Q33756929-0037BAEB-DA55-4350-8FCC-ED9F03575D46

Q33756929-1921CF50-ACF9-42F9-9139-1DD555AEB2C5

Q33756929-1DFC24A8-29C5-419A-BB2D-319D7BC97C84

Q33756929-213D60C5-2E83-4E11-BE41-8C9032A0DF76

Q33756929-2AE1CD19-7D0F-476C-AD30-AA3CEBCBABB7

Q33756929-2B5DBCD5-42CD-48F8-AC27-A38E4984C3DF

Q33756929-502F9A78-5545-4751-9F01-6631D8C5AA5F

Q33756929-523D014C-8310-4EAE-802D-A8615262A8DD

Q33756929-5A62CD12-25BC-4EC3-BF88-413214C8B4F0

Q33756929-5CFBBD97-E56B-41FE-93E3-9CDA2ED03EDC

P304

Q33756929-BC0DCDF4-F885-4452-8712-54E6F7B380DF

P31

Q33756929-08fc01e7-b04a-4239-918d-8ecadd89d84b

Q33756929-4ABB3AE0-7455-455F-9F88-3D0E6BE7FDD9

P356

Q33756929-21055499-CC9C-415C-A892-C5895A9A6545

P407

Q33756929-A61B3906-E92B-45C1-BA15-C0AE3897D8D2

P433

Q33756929-058534EA-BF99-4228-A868-0ED1092213E3

P478

Q33756929-BD9CA164-FF5E-4B4B-961A-50A5C77F914B

P577

Q33756929-E49051FB-659D-4836-9A94-D88DE9BF5309

P5875

Q33756929-6203B732-BD80-4B2A-9C83-FA1567401B18

P698

Q33756929-25C89D42-5294-461B-AA39-1BC33DBCBFC5

P921

Q33756929-675FA293-45A8-4084-A14B-E708CDA0EB19

Q33756929-DDBAD0CD-2FB9-4249-AC6A-B37487EE0996

P932

Q33756929-F8FF2797-7BBF-4D29-A8C8-16E27C99AA37

P356

J.CGH.2009.01.004

P1433

Clinical Gastroenterology and Hepatology

P1476

Risk of lymphoma associated wi ...... hn's disease: a meta-analysis.

@en

P2093

Bruce E Sands

http://www.w3.org/2001/XMLSchema#string

Corey A Siegel

http://www.w3.org/2001/XMLSchema#string

Robin J Larson

http://www.w3.org/2001/XMLSchema#string

Sadie M Marden

http://www.w3.org/2001/XMLSchema#string

Sarah M Persing

http://www.w3.org/2001/XMLSchema#string

P2860

Computed Tomography — An Increasing Source of Radiation Exposure

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Are adult patients more tolerant of treatment risks than parents of juvenile patients?

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.

P304

874-881

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2009.01.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26323240

http://www.w3.org/2001/XMLSchema#string

P698

19558997

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

2846413

http://www.w3.org/2001/XMLSchema#string